What is the Valiant Laboratories PE ratio today?
Valiant Laboratories' PE ratio is 43.5 at the 29 October 2026 close (₹128.33 a share): a market capitalisation of ₹697 crore divided by consolidated net profit of ₹16 crore over the last four quarters (Q2 FY26 to Q1 FY27).
What is the Valiant Laboratories PB ratio (price to book value)?
Valiant Laboratories' price-to-book (PB) ratio is 2.24 at the 29 October 2026 close: a market capitalisation of ₹697 crore divided by shareholders' equity (book value) of ₹311 crore on 31 March 2026. That is a book value of ₹57.24 per share against a share price of ₹128.33.
What is the Valiant Laboratories debt to equity ratio?
Valiant Laboratories' debt-to-equity ratio was 0.14 on 31 March 2026: borrowings of ₹44.9 crore against total equity of ₹311 crore. A year earlier, on 31 March 2025, it was 0.52.
What is the Valiant Laboratories market cap?
Valiant Laboratories' market capitalisation was ₹697 crore at the 29 October 2026 close: 5.43 crore shares at ₹128.33 each.
Is Valiant Laboratories debt free?
No. Valiant Laboratories had borrowings of ₹44.9 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.14. Its cash and current investments were ₹33.1 crore, so its net debt was ₹11.8 crore.
What is the Valiant Laboratories EPS?
Valiant Laboratories' basic earnings per share (EPS) were −₹0.51 in FY26.
What is the Valiant Laboratories net worth?
Valiant Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹311 crore on 31 March 2026, up 32.7% from ₹234 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹697 crore at the 29 October 2026 close.
What is the Valiant Laboratories book value per share?
Valiant Laboratories' book value per share was ₹57.24 on 31 March 2026: shareholders' equity of ₹311 crore divided by the 5.43 crore shares in issue. The share price at the 29 October 2026 close was ₹128.33.
What is the Valiant Laboratories promoter holding?
Promoters held 74.94% of Valiant Laboratories on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Valiant Laboratories ROE and ROCE?
In FY26, Valiant Laboratories' return on equity (ROE) was −1.2% and its return on capital employed (ROCE) was 0.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −0.9% and ROCE −2.1%.
What is the Valiant Laboratories shareholding pattern?
On 30 September 2026, Valiant Laboratories' shares were held by promoters 74.94%, foreign portfolio investors (FII/FPI) 0.07%, domestic institutions (DII) 0.08% (including mutual funds at 0.00%) and retail and other non-institutional investors 24.91%. Over the year, FII holding was up 0.05 percentage points from 0.02%.
What is the Valiant Laboratories free cash flow?
In FY26, Valiant Laboratories generated ₹10.4 crore of cash from operations and spent ₹34.2 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹44.6 crore. In FY25 it was −₹113 crore.
What are the Valiant Laboratories latest quarterly results?
Valiant Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 10 August 2026: consolidated net profit ₹21.1 crore; revenue from operations ₹115 crore, up 146.2% year on year.
What is the Valiant Laboratories revenue and profit in FY26?
In FY26 (April 2025–March 2026), Valiant Laboratories' consolidated net loss was ₹3.3 crore, wider than the loss of ₹2.2 crore in FY25, on revenue from operations of ₹237 crore (up 78.0%).
When are the Valiant Laboratories next results?
Valiant Laboratories will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.
How does Valiant Laboratories compare with its peers?
On FY26 consolidated figures, against Albert David, HALEOS LABS and Zim Laboratories: Valiant Laboratories' operating margin of 0.2% is the third highest of the four (Albert David −1.3%, HALEOS LABS 8.8%, Zim Laboratories 2.7%; peer average 3.4%); its return on equity of −1.2% is the lowest of the four (Albert David −0.4%, HALEOS LABS 8.4%, Zim Laboratories 2.1%; peer average 3.4%).
Valiant Laboratories vs Albert David: how do they compare?
In FY26, Valiant Laboratories earned net profit of ₹3.3 crore on revenue of ₹237 crore, against ₹1.5 crore on ₹334 crore for Albert David. Valiant Laboratories' operating margin was 0.2% (Albert David −1.3%) and its return on equity −1.2% (Albert David −0.4%). At the 29 October 2026 close, Valiant Laboratories' market capitalisation was ₹697 crore against ₹438 crore for Albert David.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
